Evidence map›Paper›PMID 33972250›Full record

ArticleAntimicrobial agents and chemotherapy2021

Trade-Offs between Antibacterial Resistance and Fitness Cost in the Production of Metallo-β-Lactamases by Enteric Bacteria Manifest as Sporadic Emergence of Carbapenem Resistance in a Clinical Setting.

Ching Hei Phoebe Cheung, Mohammed Alorabi, Fergus Hamilton, Yuiko Takebayashi, Oliver Mounsey, Kate J Heesom, Philip B Williams, O Martin Williams, Mahableshwar Albur, Alasdair P MacGowan and 1 more

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Insights into the Metabolic Adaptations of a Carbapenem-ResistantInternational journal of molecular sciences · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Ching Hei Phoebe Cheung *School of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Mohammed Alorabi *School of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Fergus HamiltonDepartment of Microbiology, Infection Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.
Yuiko TakebayashiSchool of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Oliver MounseySchool of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Kate J HeesomBristol Proteomics Facility, University of Bristol, Bristol, United Kingdom.
Philip B WilliamsBristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
O Martin WilliamsBristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
Mahableshwar AlburDepartment of Microbiology, Infection Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.
Alasdair P MacGowanDepartment of Microbiology, Infection Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.
Matthew B AvisonSchool of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom.
University of Bristol · GBNorth Bristol NHS Trust · GBUniversity Hospitals Bristol NHS Foundation Trust · GBTaif University · SA

Funding

Medical Research Council MR/N013646/1Medical Research Council MR/S004769/1Medical Research Council MR/T005408/1UKRI | Medical Research Council (MRC) MR/N013646/1UKRI | Medical Research Council (MRC) MR/S004769/1UKRI | Medical Research Council (MRC) MR/T005408/1Wellcome Trust
6 · The paper itself

Abstract

Meropenem is a clinically important antibacterial reserved for treatment of multiresistant infections. In meropenem-resistant bacteria of the family

Indexed as

beta-LactamasesGastrointestinal MicrobiomeAnti-Bacterial AgentsCarbapenemsKlebsiella pneumoniaeMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsEnterobacterKlebsiellameropenemNDM-1RamA

Identifiers

PMID33972250
PMCPMC8284430
OpenAlexW3162639645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.